Résumé

Introduction: Benign prostatic hyperplasia (BPH) is stromal and epithelial hyperplasia that increases prostate volume. This study described its epidemiological, clinical, therapeutic and outcome characteristics in 309 patients. Methodology: We conducted a retrospective descriptive study from January to December 2022. Men with clinical evidence of prostatic enlargement on digital rectal examination and histological confirmation of BPH were included. Sociodemographic, clinical, laboratory, treatment and outcome variables were analysed. Results: Among 1,888 urology consultations, 309 patients had BPH (16.3%). Mean age was 65.46 years (range: 40–93). Hypertension and diabetes were present in 23.9% and 15.5%. Urinary retention (46.6%) and dysuria (32.7%) were the main reasons for consultation; mean IPSS was 24.1. Total PSA was normal in 51.5%, and Escherichia coli was isolated in 30.4%. Alpha-blockers were prescribed to 69.3%, and 46.6% underwent surgery. All operations were transvesical prostatectomy. Wound infection (18.8%) and vesicocutaneous fistula (13.2%) were the principal complications. Mean hospital stay was 8.6 days. Conclusion: BPH is common among older men and is managed medically and/or surgically. Open surgery was associated with frequent wound infection and vesicocutaneous fistula. Functional urological endoscopy could reduce these complications.

Mot-clés :

Prostate; Alpha-Blockers; Surgery; Morbidity; University Hospital